Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
about
Somatic DNA mutation analysis in targeted therapy of solid tumoursErlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domainStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerDifferential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Mechanisms of resistance to EGFR-targeted drugs: lung cancerAfatinib for the treatment of metastatic non-small cell lung cancerMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsDifferences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutantsCancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapySimultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor.EGFR-mutated lung cancer: a paradigm of molecular oncology.Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugsDifferential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsTemporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancerMechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Other signalization targets.The EGFR family: not so prototypical receptor tyrosine kinases.Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Inhibiting epidermal growth factor receptor at a distance.Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC.AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
P2860
Q26770324-5984BA88-1A9E-4A05-A992-2BAD9E75906FQ27674725-7EA10358-8691-4B88-9B62-90DB6174E817Q27680966-55E7EB2A-283A-4B68-B945-B81BA430D779Q27851684-672E0719-51C3-4DE0-92AC-0593DAB56C68Q27853109-2BD14661-4B78-4512-90CD-82BBDA2795E3Q28075511-66F77FF6-CB66-4A61-9B0A-5D55055A24BAQ28077415-2FECEC82-16B0-4150-B326-B19D65337611Q28082181-6F50083A-DD02-4733-98DC-EC90BCBD9D8BQ28304646-0C99A933-657E-4A6A-B587-B3B1CF8A2959Q28534601-8177D7AB-E810-4C96-B397-9730DB6F1120Q30009178-67BB80D0-5954-4913-8777-90DA9B35082DQ30368961-6504803B-1925-48DD-8738-562E6BA2D021Q30850656-A25EA736-18E0-46BD-A606-B6B3920B1996Q33757134-B78C700A-3489-446D-AFF3-5EE91D80F77EQ33981031-2DE752B3-0E94-4A61-A950-E35AFC567EEBQ34406334-D312EF5C-2469-4AB7-801E-EC787806FAD2Q35059352-52B5DCFC-DF96-4C45-BC50-F293C605A653Q35967385-051C21D4-C20A-4404-B048-90011D1DD0C5Q36077604-BD606E82-9A55-43A7-B953-DD913289AE85Q36085837-C47ABB58-0912-4B84-BEE6-AD0B9F58F59FQ36368323-12DD2484-BBB5-40AD-BCB8-33E9ABB0AF25Q36511496-D886B3EF-A6D5-4C40-83F4-C5567907E5A6Q37060709-A595A9CD-3076-4354-A5A3-FE74CCBC5B1AQ38073157-1AB16A7D-604B-41DD-A1DD-FD8AE12ACFD1Q38201344-FF074A23-8C35-475F-B25F-BF7352374F43Q38335360-F86C5369-3618-4ABD-A080-32C5313360B4Q38835302-E2FA7724-3DAA-49E0-A31B-BCCFACDE2B2CQ38838227-68A0964D-BF15-4FDE-823E-D7E5D7492779Q38869420-365AAF83-35A2-464D-8068-75B1A9E02145Q38970301-24328284-D7EB-411B-AE6C-19B57D27C983Q39297048-C4CC381B-6717-4821-A80C-C6AF39ED55FCQ39493031-35D30258-5BF5-4F7D-84F3-392A64EB89E8Q46005851-8AAC55D9-4B81-470D-99EC-48F5BED40574Q51326919-7AFD77B3-73AC-4B31-BFE0-28109050E4B7Q51738393-B77B0A40-1AC1-43E0-8179-F28CB13D5285Q52365121-CCC5A1CA-7E6B-4C07-B2C1-42E899CD003FQ52684503-7E5655C6-E0FC-49EE-BAD1-93112F240D30Q54346440-CB3147C9-E569-466F-906F-6E43D6F5A2C9Q55515297-BBBD1382-406A-4EDF-B916-D957DFC1CFE4Q58704602-3AE31422-2C7F-49EA-9063-DCD797234B54
P2860
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Structural and mechanistic und ...... in non-small cell lung cancer.
@ast
Structural and mechanistic und ...... in non-small cell lung cancer.
@en
type
label
Structural and mechanistic und ...... in non-small cell lung cancer.
@ast
Structural and mechanistic und ...... in non-small cell lung cancer.
@en
prefLabel
Structural and mechanistic und ...... in non-small cell lung cancer.
@ast
Structural and mechanistic und ...... in non-small cell lung cancer.
@en
P2860
P1476
Structural and mechanistic und ...... in non-small cell lung cancer.
@en
P2093
Cai-Hong Yun
Michael J Eck
P2860
P304
P356
10.1016/J.BBAPAP.2009.12.010
P407
P577
2009-12-22T00:00:00Z